Anchor-based classification and type-C inhibitors for tyrosine kinases
Explore this paper's citation graph
Summary
An anchor-based classification for tyrosine kinases is presented and two type-C inhibitors, namely rosmarinic acid and EGCG, which occupy two and one specific anchors, respectively, are discovered by screening 118,759 natural compounds.
- Type
- article
- Published
- 2015-06-16
- Cited by
- 14
- References
- 55
- Access
- Open access
- OpenAlex
- https://openalex.org/W649798993
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:3443197
Keywords
Kinase, Tyrosine kinase, Syk, Drug discovery, Biochemistry
References
- Tyrosine kinases as targets for cancer therapy.
- Review: side effects of approved molecular targeted therapies in solid cancers.
- Design and synthesis of tetrahydropyridothieno[2,3-d]pyrimidine scaffold based epidermal growth factor receptor (EGFR) kinase inhibitors: the role of side chain chirality and Michael acceptor group for maximal potency.
- Imatinib-resistant chronic myeloid leukemia (CML): Current concepts on pathogenesis and new emerging pharmacologic approaches
- Identification of residues in the nucleotide binding site of the epidermal growth factor receptor/kinase.
- Kinase Drug Discovery – What’s Next in the Field?
- Exploring Off-Targets and Off-Systems for Adverse Drug Reactions via Chemical-Protein Interactome — Clozapine-Induced Agranulocytosis as a Case Study
- Oncogenic JAK1 and JAK2-activating mutations resistant to ATP-competitive inhibitors
- The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib
- Non-receptor protein tyrosine kinases signaling pathways in normal and cancer cells
- Rhebbing up mTOR: New Insights on TSC1 and TSC2, and the Pathogenesis of Tuberous Sclerosis
- The biology of VEGF and its receptors
- Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain
- EGFR mutation and resistance of non-small-cell lung cancer to gefitinib.
- Core Site-Moiety Maps Reveal Inhibitors and Binding Mechanisms of Orthologous Proteins by Screening Compound Libraries
- Atom pairs as molecular features in structure-activity studies: definition and applications
- The Protein Kinase Complement of the Human Genome
- Acquired resistance to tyrosine kinase inhibitors during cancer therapy.
- The (un)targeted cancer kinome.
- Molecular recognition of protein kinase binding pockets for design of potent and selective kinase inhibitors.
Cited by
- Exploration for novel inhibitors showing back-to-front approach against VEGFR-2 kinase domain (4AG8) employing molecular docking mechanism and molecular dynamics simulations
- An integrated approach with new strategies for QSAR models and lead optimization
- In Vitro and In Silico Studies of the Molecular Interactions of Epigallocatechin-3-O-gallate (EGCG) with Proteins That Explain the Health Benefits of Green Tea
- Zika Virus NS3 Protease Pharmacophore Anchor Model and Drug Discovery
- A site-moiety map and virtual screening approach for discovery of novel 5-LOX inhibitors
- A Chemical Probe for Dark Kinase STK17B Derives its Potency and High Selectivity Through a Unique P-loop Conformation
- Phthalazine‐based VEGFR‐2 inhibitors: Rationale, design, synthesis, in silico, ADMET profile, docking, and anticancer evaluations
- Salvia Biotechnology
- Rosmarinic Acid and Related Dietary Supplements: Potential Applications in the Prevention and Treatment of Cancer
- The potential of epigallocatechin gallate in the chemoprevention and therapy of hepatocellular carcinoma
- Rosmarinic acid suppresses the progression of COPD via Syk by modulating airway inflammation and epithelial apoptosis in vivo and in vitro
- From nature to novelty: Enhancing rosmarinic acid's therapeutic potential through smart molecular design.
- A Chemical Probe for Dark Kinase STK17B Derives its Potency and High Selectivity Through a Unique P-loop Conformation
- Anticancer Activity of Salvia miltiorrhiza and Its Secondary Metabolites
Related papers
- Hematopoietic or Osteoclast-Specific Deletion of Syk Leads to Increased Bone Mass in Experimental Mice
- Rapid ubiquitination of Syk following GPVI activation in platelets.
- Crystal structures of spleen tyrosine kinase in complex with novel inhibitors: structural insights for design of anticancer drugs
- Aerosolized Syk Antisense Suppresses Syk Expression, Mediator Release from Macrophages, and Pulmonary Inflammation1
- Review and prospects of targeted therapies for Spleen tyrosine kinase (SYK).
- Role of docking in anticancer drug discovery
- Involvement of Src and Syk Tyrosine Kinases in HIV-1 Transfer from Dendritic Cells to CD4+ T Lymphocytes1
- Targeting Spleen Tyrosine Kinase-Bruton's Tyrosine Kinase Axis for Immunologically Mediated Glomerulonephritis
- The monocyte Fcγ receptors FcγRI/γ and FcγRIIA differ in their interaction with Syk and with Src‐related tyrosine kinases